Toxicity management of systemic kidney cancer therapies
Q Qin, E Nein, A Flaten… - Hematology/Oncology …, 2023 - hemonc.theclinics.com
Multiple systemic therapies are available for the treatment of metastatic renal cell carcinoma
(mRCC), including mammalian target of rapamycin (mTOR), vascular endothelial growth …
(mRCC), including mammalian target of rapamycin (mTOR), vascular endothelial growth …